^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CPO301

    i
    Other names: CPO301, SYS6010, CPO 301, CPO-301, SYS 6010, SYS-6010
    Associations

    News

    Trials
    Company:
    CSPC Pharma
    Drug class:
    Topoisomerase I inhibitor, EGFR-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    11d
    A Phase Ib/II Study on the Safety and Efficacy of SYS6010 and SYS6010 in Combination with SYH2051±Bevacizumab in Patients with Advanced Solid Tumors (ChiCTR2500100723)
    P1/2, N=138, Not yet recruiting, Sun Yat-sen University Cancer Center, Fujian Provincial Cancer Hospital; CSPC Megalith Biopharmaceutical Co., Ltd..
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR expression • EGFR positive
    |
    Avastin (bevacizumab) • CPO301
    3ms
    A Phase Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Dosing Regimens of SYS6010 in Patients with Advanced Solid Tumors (ChiCTR2500099933)
    P1/2, N=199, Recruiting, Fujian Provincial Cancer Hospital; CSPC Megalith Biopharmaceutical Co., Ltd..
    New P1/2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression • EGFR positive
    |
    CPO301
    almost2years
    A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=102, Recruiting, Conjupro Biotherapeutics, Inc.
    New P1 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    EGFR mutation • KRAS wild-type • RAS wild-type
    |
    CPO301